Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Rodbard

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Therapeutic Advances in Musculoskeletal Disease|April 14, 2026
Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 DiabetesAndrew I Spitzer, Helena Rodbard
Advances in Therapy|January 6, 2019
Optimizing Fixed-Ratio Combination Therapy in Type 2 DiabetesLeigh Perreault, Helena Rodbard, Virginia Valentine, et al.
Endocrinology, Diabetes & Metabolism|March 17, 2022
Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?Matthias Blüher, Antonio Ceriello, Melanie Davies, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Musculoskeletal Disease|April 14, 2026
Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 DiabetesAndrew I Spitzer, Helena Rodbard
Advances in Therapy|January 6, 2019
Optimizing Fixed-Ratio Combination Therapy in Type 2 DiabetesLeigh Perreault, Helena Rodbard, Virginia Valentine, et al.
Endocrinology, Diabetes & Metabolism|March 17, 2022
Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?Matthias Blüher, Antonio Ceriello, Melanie Davies, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Pageof 1